Antipsychotic Agents

Haddad and Winchester's Clinical Management of Poisoning and Drug Overdose, Fourth Edition

Volumn , Issue , 2007, Pages 703-720

  Levine, Michael ^a,b   Burns, Michael J ^a,c  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 79960757009     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-7216-0693-4.50043-8     Document Type: Chapter

References (182)

1. RJ Baldessarini and FI Tarazi (2001) Drugs and the treatment of psychiatric disorders: psychosis and mania. JG Hardman, LE Limbrid, AG Gilman (Eds) Goodman & Gilman's The Pharmacological Basis of Therapeutics 10th ed. New York: McGraw-Hill 485-520.
2. N Buckley and P McManus (1998) Fatal toxicity of drugs used in the treatment of psychotic illnesses. Br J Psychiatry 172 461-464.
3. NA Buckley, IM Whyte and AH Dawson (1995) Thioridazine has greater cardiotoxicity in overdose than other neuroleptics. J Toxicol Clin Toxicol 33 199-204.
4. D Schreinzer, R Frey, T Stimpfl, et al. (2001) Different fatal toxicity of neuroleptics identified by autopsy. Eur Neuropsychopharmacol 11 117-124.
5. WA Watson, TL Litovitz, GC Rodger, et al. (2005) 2004 annual report of the American Association of Poison Control Centers Toxic Exposure Surveillance System. Am J Emerg Med 23 589-666.
6. E Richelson (1999) Receptor pharmacology of neuroleptics: relation to clinical effects. J Clin Psychiatry 60(Suppl 10), 5-14.
7. O Blin (1999) A comparative review of new antipsychotics. Can J Psychiatry 44 235-244.
8. MD Jibson and R Tandon (1998) New atypical antipsychotic medications. J Psychiatr Res 32 215-218.
9. R Tandon, K Milner and MD Jibson (1999) Antipsychotics from theory to practice: integrating clinical and basic data. J Clin Psychiatry 60(Suppl 8), 21-28.
10. RL Borison (1997) Recent advances in the pharmacotherapy of schizophrenia. Harvard Rev Psychiatry 4 255-271.
11. P Seeman, T Lee, M Chau-Wong and K Wong (1976) Antipsychotic drug doses and neuroleptic dopamine receptors. Nature 261 717-719.
12. L Farde, AL Nordstrom, FA Wiesel, et al. (1992) Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects. Arch Gen Psychiatry 49 538-544.
13. JL Black and E Richelson (1987) Antipsychotic drugs: prediction of side effect profiles based on neuroreceptor data derived from human brain tissue. Mayo Clin Proc 62 369-372.
14. DE Casey (1997) The relationship of pharmacology to side effects. J Clin Psychiatry 58(Suppl 10), 55-62.
15. HY Meltzer, Z Li, Y Kaneda, et al. (2003) Serotonin receptors: their key role in drugs to treat schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 27 1159-1172.
16. S Kapur and G Remington (1996) Serotonin-dopamine interaction and its relevance to schizophrenia. Am J Psychiatry 153 466-476.
17. BJ Kinon and JA Lieberman (1996) Mechanisms of action of atypical antipsychotic drugs: a critical analysis. Psychopharmacology 124 2-34.
18. SC Risch (1996) Pathophysiology of schizophrenia and the role of newer antipsychotics. Pharmacotherapy 16(Suppl), 11-14.
19. N Ogata and T Narahashi (1989) Block of sodium channels by psychotropic drugs in single guinea-pig cardiac myocytes. Br J Pharmacol 97 905-913.
20. B Drolet, F Cincet, J Rail, et al. (1999) Thioridazine lengthens repolarization of cardiac ventricular myocytes by blocking the delayed rectifier potassium current. J Pharmacol Exp Ther 288 1261-1268.
21. D Rampe, K Murawsky, J Grau and EW Lewis (1998) The antipsychotic agent sertindole is a high affinity antagonist of the human cardiac potassium channel HERG. J Pharmacol Exp Ther 286 788-793.
22. RJ Gould, KMM Murphy, IJ Reynolds, et al. (1983) Antischizophrenic drugs of the diphenylbutylpiperidine type act as calcium channel antagonists. Proc Natl Acad Sci U S A 86 5122-5125.
23. J Logothetis (1967) Spontaneous epileptic seizures and electroencephalographic changes in the course of phenothiazine therapy. Neurology 17 869.
24. JA Cold, BG Wills and JH Froemming (1990) Seizure activity associated with antipsychotic therapy. DICP 24 601-606.
25. D Hedges, K Jeppson and P Whitehead (2003) Antipsychotic medication and seizures: a review. Drugs Today (Barc) 39 551-557.
26. F Pisani, G Oteri, C Costa, et al. (2002) Effects of psychotropic drugs on seizure threshold. Drug Saf 25 91-110.
27. BK Alldredge (1999) Seizure risk associated with psychotropic drugs: clinical and pharmacokinetic considerations. Neurology 53(Suppl 2), 68-75.
28. C Peterson (1981) Seizures induced by acute loxapine overdose. Am J Psychiatry 138 1089-1091.
29. D Devinsky, G Honigfeld and J Patin (1991) Clozapine-related seizures. Neurology 41 369-371.
30. CD Marsden and P Jenner (1980) The pathophysiology of extrapyramidal side-effects of neuroleptic drugs. Psychol Med 10 55-72.
31. RJ Baldessarini and D Tarsy (1980) Dopamine and the pathophysiology of dyskinesia induced by antipsychotic drugs. Ann Rev Neurosci 3 23-41.
32. A Carlsson, N Walters and ML Carlsson (1999) Neurotransmitter interactions in schizophrenia—therapeutic implications. Biol Psychiatry 46 1388-1395.
33. NMJ Rupniak, P Jenner and CD Marsden (1986) Acute dystonia induced by neuroleptic drugs. Psychopharmacology 88 403-419.
34. H Kolbe, A Clow, P Jenner, et al. (1981) Neuroleptic-induced acute dystonic reactions may be due to enhanced dopamine release or to supersensitive postsynaptic receptors. Neurology 31 434-439.
35. SC Mann, SN Caroff and A Lazarus (1991) Pathogenesis of neuroleptic malignant syndrome. Psychiatr Ann 21 175-180.
36. VW Henderson and GF Wooten (1981) Neuroleptic malignant syndrome: a pathophysiologic role for the dopamine receptor blockade? Neurology 1331 132-137.
37. M Ebadi, RF Pfeiffer and LC Murrin (1990) Pathogenesis and treatment of neuroleptic malignant syndrome. Gen Pharmacol 21 367-386.
38. O Lindvall, A Bjorklung and G Skagerberg (1983) Dopamine-containing neurons in the spinal cord: anatomy of some functional aspects. Ann Neurol 14 255-260.
39. JC Stoof and JW Kebabian (1984) Two dopamine receptors: biochemistry, physiology and pharmacology. Life Sci 34 2281-2286.
40. PI Rosebush and MF Mazurak (1991) Serum iron and neuroleptic malignant syndrome. Lancet 338 149-151.
41. FM Garcia, J Duarte, A Perez, et al. (1993) Low serum iron and neuroleptic malignant syndrome. Ann Pharmacother 27 101-102.
42. JI Javid (1994) Clinical pharmacokinetics of antipsychotics. J Pharmacol 34 286-295.
43. L Ereshefsky (1996) Pharmacokinetics and drug interactions: update for new antipsychotics. J Clin Psychiatry 57(Suppl 11), 12-25.
44. J Fang and JW Gorrod (1999) Metabolism, pharmacogenetics, and metabolic drug-drug interactions of antipsychotic drugs. Cell Mol Neurobiol 19 491-510.
45. Micromedex Healthcare Series, Vol. 123. DRUGDEX drug evaluations, Risperdal Consta. Greenwood Village, CO, Thomson MICROMEDEX, 2004. Accessed December 29, 2004.
46. L Howard, R Webb and K Abel (2004) Safety of antipsychotic drugs for pregnant and breastfeeding women with non-affective psychosis [Editorial]. BMJ 329 933-934.
47. ML Dahl (2002) Cytochrome p450 phenotyping/genotyping in patients receiving antipsychotics: useful aid to prescribing? Clin Pharmacokinet 41 453-470.
48. N Ozaki (2004) Pharmacogenetics of antipsychotics. Nagoya J Med Sci 67 1-7.
49. DC Goff and RJ Baldessarini (1993) Drug interactions with antipsychotic agents. J Clin Psychopharmacol 13 57-67.
50. A Klimke and E Klieser (1994) Sudden death after intravenous application of lorazepam in a patient treated with clozapine. Am J Psychiatry 151 780.
51. N Berry, S Pradhan, R Sagar, et al. (2003) Neuroleptic malignant syndrome in an adolescent receiving olanzapine-lithium combination therapy. Pharmacotherapy 23 255-259.
52. JK Joseph and K Thomas (1991) Lithium toxicity—a risk factor for neuroleptic malignant syndrome. J Assoc Physicians India 39 572-573.
53. A Trenton, G Currier and F Zwemer (2003) Fatalities associated with therapeutic use and overdose of atypical antipsychotics. CNS Drugs 17 307-324.
54. S Mady, P Wax, D Wang, et al. (1996) Pediatric clozapine intoxication. Am J Emerg Med 14 462-463.
55. L Yip, RC Dart and K Graham (1998) Olanzapine toxicity in a toddler [Letter]. Pediatrics 102 1494.
56. GR Bond and JD Thompson (1999) Olanzapine pediatric overdose [Letter]. Ann Emerg Med 34 292-293.
57. MJ Burns (2001) The pharmacology and toxicology of atypical antipsychotic agents. J Toxicol Clin Toxicol 39 1-14.
58. M Parsons and NA Buckley (1997) Antipsychotic drugs in overdose: practical management guidelines. CNS Drugs 6 427-441.
59. AA Acri and FM Henretig (1998) Effects of risperidone in overdose. Am J Emerg Med 16 498-501.
60. I LeBlaye, B Donatini, M Hall, et al. (1992) Acute overdosage with clozapine: a review of the available clinical experience. Pharm Med 6 169-178.
61. GCF O'Malley, S Seifert, K Heard, et al. (1999) Olanzapine overdose mimicking opioid intoxication. Ann Emerg Med 34 279-281.
62. TJ Harmon, JG Benitez, EP Krenzelok, et al. (1998) Loss of consciousness from acute quetiapine overdosage. J Toxicol Clin Toxicol 36 599-602.
63. D Barry, FL Meyskens and CE Becker (1973) Phenothiazine poisoning: a review of 48 cases. Calif Med 118 1-5.
64. MM Bonin and KK Burkhart (1999) Olanzapine overdose in a 1-year old male. Pediatr Emerg Care 15 266-267.
65. KS Dyer and AD Woolf (1999) Use of phenothiazines as sedatives in children: what are the risks? Drug Saf 21 81-90.
66. C Li and WB Gefter (1992) Acute pulmonary edema induced by overdosage of phenothiazines. Chest 101 102-104.
67. AA Mitchell, FH Lovejoy and P Goldman (1976) Drug ingestions associated with miosis in comatose children. J Pediatr 89 303.
68. U Elkayam and W Frishman (1980) Cardiovascular effects of phenothiazines. Am Heart J 100 397-401.
69. ND Fowler, D McCall, T Chou, et al. (1981) Electrocardiographic changes and cardiac arrhythmias in patients receiving psychotropic drugs. Am J Cardiol 37 223-230.
70. GF Fletcher, TM Kazamias and NK Wenger (1961) Cardiotoxic effects of Mellaril: conduction disturbances and supraventricular arrhythmias. Am Heart J 78 135-138.
71. CC Thornton and MH Wendkos (1971) EKG T-wave distortions among thioridazine-treated psychiatric inpatients. Dis Nerv Syst 32 320-323.
72. MA Frye, MF Coudreaut, SM Hakeman, et al. (1995) Continuous droperidol infusion for management of agitated delirium in an intensive care unit. Psychosomatics 36 301-305.
73. RR Riker, GL Fraser and PM Cox (1994) Continuous infusion of haloperidol controls agitation in critically ill patients. Crit Care Med 22 433-440.
74. SI Krahenbuhl, B Sauter, H Kupferschmidt, et al. (1995) Reversible QT prolongation with torsades de pointes in a patient with pimozide intoxication. Am J Med Sci 309 315-316.
75. DT Hulisz, SL Dasa, LD Black, et al. (1994) Complete heart block and torsade de pointes associated with thioridazine poisoning. Pharmacotherapy 14 239-245.
76. JL Wilt, AM Minnema, RF Johnson, et al. (1993) Torsade de pointes associated with the use of intravenous haloperidol. Ann Intern Med 119 391-394.
77. ND Sharma, HS Rosman, D Padhi and JE Tisdale (1998) Torsades de pointes associated with intravenous haloperidol in critically ill patients. Am J Cardiol 81 238-240.
78. TA Cheslik and J Erramouspe (1996) Extrapyramidal symptoms following accidental ingestion of risperidone in a child. Ann Pharmacother 30 360-363.
79. G Muscettola, G Barbato, S Pampallona, et al. (1999) Extrapyramidal syndromes in neuroleptic-treated patients: prevalence, risk factors, and association with tardive dyskinesia. J Clin Psychopharmacol 19 203-208.
80. M Balestrieri, C Vampini and C Bellantuono (2000) Efficacy and safety of novel antipsychotics: a critical review. Hum Psychopharmacol Clin Exp 15 499-512.
81. L Cortese, E Pourcher-Bouchard and R Williams (1998) Assessment and management of antipsychotic-induced adverse events. Can J Psychiatry 43(Suppl 1), 15-20.
82. RJ Koek and HP Edmond (1989) Acute laryngeal dystonic reactions to neuroleptics. Psychosomatics 30 359-364.
83. C Swett (1982) Drug-induced dystonia. Am J Psychiatry 132 532-534.
84. FJ Ayd (1961) A survey of drug-induced extrapyramidal reactions. JAMA 175 1054-1060.
85. JM Gupta and FH Lovejoy (1967) Acute phenothiazine toxicity in childhood: a five-year survey. Pediatrics 39 771.
86. AM Hegarty, RB Lipton, AE Merriam, et al. (1991) Cocaine as a risk factor for acute dystonic reactions. Neurology 41 1670-1672.
87. E Freed (1981) Alcohol-triggered neuroleptic-induced tremor, rigidity and dystonia. Med J Aust 2 44-45.
88. DE Nelson (2001) Akathisia—a brief review. Scott Med J 46 133-134.
89. M Kurz, M Hummer, H Oberbauer and WW Fleischhacker (1995) Extrapyramidal side effects of clozapine and haloperidol. Psychopharmacology 118 52-56.
90. RM Kobayashi (1977) Drug therapy of tardive dyskinesia. N Engl J Med 296 257.
91. R Yassa, J Ananth, S Cordozo, et al. (1983) Tardive dyskinesia in an outpatient population: prevalence and predisposing factors. Can J Psychiatry 28 391-394.
92. D Nierenberg, M Disch, E Manheimer, et al. (1991) Facilitating prompt diagnosis and treatment of the neuroleptic malignant syndrome. Clin Pharmacol Ther 50 580-586.
93. DF Levinson and GM Simpson (1986) Neuroleptic-induced extrapyramidal symptoms with fever: heterogeneity of the “neuroleptic malignant syndrome.”. Arch Gen Psychiatry 43 839-848.
94. G Addonizio, VL Susman and SD Roth (1987) Neuroleptic malignant syndrome: review and analysis of 115 cases. Biol Psychiatry 22 1004-1020.
95. SN Caroff and SC Mann (1993) Neuroleptic malignant syndrome. Med Clin North Am 77 185-202.
96. A Shalev and H Munitz (1986) The neuroleptic malignant syndrome: agent and host interaction. Acta Psychiatr Scand 73 337-347.
97. RR Silva, DM Munoz, M Alpert, et al. (1999) Neuroleptic malignant syndrome in children and adolescents. J Am Acad Adolesc Psychiatry 38 187-194.
98. CA Pearlman (1986) Neuroleptic malignant syndrome: a review of the literature. J Clin Psychopharmacol 6 257-273.
99. AL Pelonero, JL Levenson and AK Pandurangi (1998) Neuroleptic malignant syndrome: a review. Psychiatr Serv 49 1163-1172.
100. VR Velamoor, RMG Norman, SN Caroff, et al. (1994) Progression of symptoms in neuroleptic malignant syndrome. J Nerv Ment Dis 182 168-173.
101. PE Keck, HG Pope and SL McElroy (1991) Declining frequency of neuroleptic malignant syndrome in a hospital population. Am J Psychiatry 148 880-882.
102. AMP Kellam (1990) The (frequently) neuroleptic (potentially) malignant syndrome. Br J Psychiatry 157 169-173.
103. DS Ravin and JW Levenson (1997) Fatal cardiac event following initiation of risperidone therapy. Ann Pharmacother 31(7–8), 867-870.
104. OP Mehtonen, K Aranko, L Malkonen, et al. (1991) A survey of sudden death associated with the use of antipsychotic or antidepressant drugs: 49 cases in Finland. Acta Psychiatr Scand 84 58-64.
105. LE Hollister and JV Kosek (1965) Sudden death during treatment with phenothiazine derivatives. JAMA 192 1035-1038.
106. AM Lee, JL Knoll and R Suppes (1997) The atypical antipsychotic sertindole: a case series. J Clin Psychiatry 58 410-416.
107. K Brown, H Levy, C Brenner, et al. (1993) Overdose of risperidone. Ann Emerg Med 22 1908-1910.
108. S Lynch, S Fill and RS Hoffman (1999) Intentional quetiapine (Seroquel) overdose [Abstract]. J Toxicol Clin Toxicol 37 631.
109. FM Hustey (1999) Acute quetiapine poisoning. J Emerg Med 17 995-997.
110. LC Kopala, C Day, B Dillman and D Gardner (1998) A case of risperidone overdose in early schizophrenia: a review of potential complications. J Psychiatry Neurosci 23 305-308.
111. MY Flugelman, A Tal, S Pollack, et al. (1985) Psychotropic drugs and long QT syndromes: case reports. J Clin Psychiatry 46 290-291.
112. NA Aunsholt (1989) Prolonged QT interval and hypokalemia caused by haloperidol. Acta Psychiatr Scand 79 411-412.
113. KR Lawrence and SA Nasraway (1997) Conduction disturbances associated with administration of butyrophenone antipsychotics in the critically ill: a review of the literature. Pharmacotherapy 17 531-537.
114. V Lischke, M Behne, P Doelken, et al. (1994) Droperidol causes a dose-dependent prolongation of the QT interval. Anesth Analg 79 983-986.
115. MedWatch 2001 Safety Information Summaries: Inapsine (Droperidol). Accessed January 16, 2005, from http://www.fda.gov/medwatch/safety/2001/safety01.htm#inapsi.
116. AH Glassman and JT Bigger Jr (2001) Antipsychotic drugs: prolonged QT interval, torsades de pointes, and sudden death. Am J Psychiatry 158 1774-1782.
117. PM Haddad and IM Anderson (2002) Antipsychotic-related QTc prolongation, torsades de pointes and sudden death. Drugs 62 1649-1671.
118. Anonymous (1994) Clozapine and myocarditis. WHO Drug Information 8 212-213.
119. DB Merrill, GW Dec and DC Goff (2005) Adverse cardiac effects associated with clozapine. J Clin Psychopharmacol 25 32-41.
120. HE Lebovitz (2003) Metabolic consequences of atypical antipsychotic drugs. Psychiatr Q 74 277-290.
121. KA Liebzeit (2001) New onset diabetes and atypical antipsychotics. Eur Neuropsychopharmacol 11 25-32.
122. F Gianfrancesco, R White, W Ruey-hua, et al. (2003) Antipsychotic-induced type 2 diabetes: evidence from a large health plan database. J Clin Psychopharmacol 23 328-335.
123. LL Citrone and AB Jaffe (2003) Relationship of atypical antipsychotics with development of diabetes mellitus. Ann Pharmacother 37 1849-1857.
124. EF Torrey and CI Swalwell (2003) Fatal olanzapine-induced ketoacidosis. Am J Psychiatry 160 2241.
125. EA Koller and PM Doraiswamy (2002) Olanzapine-associated diabetes mellitus. Pharmacotherapy 22 841-852.
126. J Avella, CV Wetli, JC Wilson, et al. (2004) Fatal olanzapine-induced hyperglycemia. Am J Forensic Med Pathol 25 172-175.
127. R Meatherall and J Younes (2002) Fatality from olanzapine-induced hyperglycemia. J Forensic Sci 47 893-896.
128. HJ Wehring, DL Kelly, RC Love, et al. (2003) Deaths from diabetic ketoacidosis after long-term clozapine treatment. Am J Psychiatry 160 2241-2242.
129. E Koller, B Schneider, K Bennett, et al. (2001) Clozapine-associated diabetes. Am J Med 15 716-723.
130. MM Iqbal, A Rahman, K Husain, et al. (2003) Clozapine: a clinical review of adverse effects and management. Ann Clin Psychiatry 15 33-48.
131. DW Haupt and JW Newcomer (2001) Hyperglycemia and antipsychotic medications. J Clin Psychiatry 62(Suppl 27), 15-26.
132. JM Meyer (2001) Novel antipsychotics and severe hyperlipidemia. J Clin Psychopharmacol 21 369-374.
133. SE Domon and JC Webber (2001) Hyperglycemia and hypertriglyceridemia secondary to olanzapine. J Clin Adolesc Psychopharmacol 11 285-288.
134. SJ Kingsbury, M Fayek and D Trufasiu (2001) The apparent effects of ziprasidone on plasma lipids and glucose. J Clin Psychiatry 62 347-349.
135. EM Haberfellner and T Honsig (2003) Nonalcoholic steatohepatitis: a possible side effect of atypical antipsychotics. J Clin Psychiatry 64 851.
136. EA Koller, JT Cross and PM Doraiswamy (2003) Pancreatitis associated with atypical antipsychotics: from the Food and Drug Administration's Med Watch surveillance system and published reports. Pharmacotherapy 23 1123-1130.
137. K Selem and N Kaplowitz (1999) Hepatotoxicity of psychotropic drugs. Hepatology 29 1347-1351.
138. M Hummer, M Kurz, I Kurzthalaer, et al. (1997) Hepatotoxicity of clozapine. J Clin Psychopharmacol 17 314-317.
139. AB Whitworth, D Liensberger and WW Fleischhacker (1999) Transient increase of liver enzymes induced by risperidone: two case reports [Letter]. J Clin Psychopharmacol 19 475-476.
140. WH Trayle (1986) Phenothiazine-induced agranulocytosis [Letter]. JAMA 256 1957.
141. P Wren, LA Frizzell, NL Keltner, et al. (2003) Three potentially fatal adverse effects of psychotropic medications. Perspect Psychiatr Care 39 75-81.
142. R Litvak and R Kaelbling (1971) Agranulocytosis, leukopenia and psychotropic drugs. Arch Gen Psychiatry 24 265-267.
143. J Alvir, J Lieberman, A Safferman, et al. (1993) Clozapine-induced agranulocytosis; incidence and risk factors in the United States. N Engl J Med 329 162-167.
144. SL Gerson (1994) G-CSF and the management of clozapine-induced agranulocytosis. J Clin Psychiatry 55(Suppl B), 139-142.
145. A Steinwachs, R Grohmann, F Pedrosa, et al. (1999) Two cases of olanzapine-induced reversible neutropenia. Pharmacopsychiatry 32 154-156.
146. HG Ruhe, HE Becker and P Jessurun (2001) Agranulocytosis and granulocytopenia associated with quetiapine. Acta Psychiatr Scand 104 311-313.
147. Z Dernovsek and P Tavcar (1997) Risperidone-induced leucopenia and neutropenia. Br J Psychiatry 171 393-394.
148. S Hagg, O Spigset and TG Soderstrom (2000) Association of venous thromboembolism and clozapine. Lancet 355 1155-1156.
149. FM Forrest, IS Forrest and AS Mason (1961) Review of rapid urine tests for phenothiazine and related drugs. Am J Psychiatry 118 300-307.
150. KL Sloan, VM Haver and AJ Saxon (2000) Quetiapine and false-positive urine drug testing for tricyclic antidepressants [Letter]. Am J Psychiatry 157 148-149.
151. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, 4th ed. Washington, DC, American Psychiatric Association, 1994, pp 739–742.
152. P Adnet, P Lestavel and R Krivosic-Horber (2000) Neuroleptic malignant syndrome. Br J Anaesth 85 129-135.
153. TE Albertson, A Dawson, FJ de Latorre, et al. (2001) TOX-ACLS: toxicologic-oriented advanced cardiac life support. Ann Emerg Med 37(Suppl 4), 78-90.
154. T Kawamura, I Kodama, J Toyama, et al. (1990) Combined application of class I antiarrhythmic drugs causes “additive,” “reductive,” or “synergistic” sodium channel block in cardiac muscles. Cardiovasc Res 24 925-931.
155. BL Tranum and ML Murphy (1969) Successful treatment of ventricular tachycardia associated with thioridazine (Mellaril). South Med J 62 357-358.
156. J Lumpkin, AS Watanabe, BH Rumack, et al. (1979) Phenothiazine-induced ventricular tachycardia following acute overdose. JACEP 8 476-478.
157. DA Pietro (1981) Thioridazine-associated ventricular tachycardia and isoproterenol [Letter]. Ann Intern Med 94 411.
158. A Kemper, R Dunlop and D Pietro (1983) Thioridazine-induced torsades de pointes successful therapy with isoproterenol. JAMA 249 2931-2934.
159. MJ Burns, CH Linden, A Graudins, et al. (2000) A comparison of physostigmine and benzodiazepines for the treatment of anticholinergic poisoning. Ann Emerg Med 35 374-381.
160. P Schuster, E Gabriel, B Luefferie, et al. (1977) Reversal by physostigmine of clozapine-induced delirium. Clin Toxicol 10 437-441.
161. K Corre, J Neimann and H Bessen (1984) Extended therapy for acute dystonic reactions. Ann Emerg Med 13 194-197.
162. DR Vinson and DL Drotts (2001) Diphenhydramine for the prevention of akathisia induced by prochlorperazine: a randomized, controlled trial. Ann Emerg Med 37 125-131.
163. AR Lima, KV Weiser, J Bacaltchuk and TR Barnes (2004) Anticholinergics for neuroleptic-induced akathisia. Cochrane Database Syst Rev 1 CD003727.
164. L Adler, B Angrist, E Peselow, et al. (1983) A controlled assessment of propranolol in the treatment of neuroleptic-induced akathisia. Br J Psychiatry 149 42-45.
165. GS Zubenko, BM Cohen, JF Lipinski, et al. (1985) Use of clonidine in treating neuroleptic-induced akathisia [Letter]. Psychiatry Res 13 253.
166. T Fischel, H Hermesh, D Aizenberg, et al. (2001) Cyproheptadine versus propranolol for the treatment of acute neuroleptic-induced akathisia: a comparative double-blind study. J Clin Psychopharmacol 21 612-615.
167. CH Miller and WW Fleischhacker (2000) Managing antipsychotic-induced acute and chronic akathisia. Drug Saf 22 73-81.
168. PS Sachdev (2000) The current status of tardive dyskinesia. Aust N Z J Psychiatry 34 355-369.
169. VL Susman (2001) Clinical management of neuroleptic malignant syndrome. Psychiatr Q 72 325-336.
170. BH Guze and LR Baxter (1985) Neuroleptic malignant syndrome. N Engl J Med 313 163-166.
171. T Krause, MU Gerbershagen, M Fiege, et al. (2004) Dantrolene—a review of its pharmacology, therapeutic use and new developments. Anaesthesia 59 364-373.
172. VR Velamoor, GN Swamy, L.-R.S. Parmar Late-RS, et al. (1995) Management of suspected neuroleptic malignant syndrome. Can J Psychiatry 40 545-550.
173. S Dhib-Jalbut, R Hesselbrock, MM Mouradian, et al. (1987) Bromocriptine treatment of neuroleptic malignant syndrome. J Clin Psychiatry 48 69-73.
174. MR Rosenberg and M Green (1989) Neuroleptic malignant syndrome: review of response to therapy. Arch Intern Med 149 1927-1931.
175. PI Rosebush, TD Stewart and MF Marzurek (1991) The treatment of neuroleptic malignant syndrome: are dantrolene and bromocriptine useful adjuncts to supportive care? Br J Psychiatry 159 709-712.
176. P Sakkas, JM Davis, J Hua, et al. (1991) Pharmacotherapy of neuroleptic malignant syndrome. Psychiatr Ann 21 157-164.
177. P Sakkas, JM Davis, PG Janicak, et al. (1991) Drug treatment of the neuroleptic malignant syndrome. Psychopharmacol Bull 27 381-384.
178. JM Davis, PG Janicak, P Sakkas, et al. (1991) Electroconvulsive therapy in the treatment of the neuroleptic malignant syndrome. Convuls Ther 7 111-120.
179. R Sangai and R Dimitrijevic (1985) Neuroleptic malignant syndrome: successful treatment with pancuronium. JAMA 254 2795-2796.
180. V Khaldarov (2000) Benzodiazepines for treatment of neuroleptic malignant syndrome. Hosp Physician 36 51-55.
181. KD Burris, FR Molski, C Xu, et al. (2002) Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors. J Pharmacol Exp Ther 302 381-389.
182. RC Baselt (2004) Disposition of Toxic Drugs and Chemicals in Man 7th ed. Foster City, CA: Biomedical Publications